DUBLIN--(BUSINESS WIRE)--
Research and Markets (http://www.researchandmarkets.com/research/5qlwpl/lyrica_epilepsy) has announced a new report "Lyrica (Epilepsy) - Forecast and Market Analysis to 2022" to their offering.
Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB's Keppra and GlaxoSmithKline's Lamictal. Although both drugs have experienced significant generic erosion, they form the mainstay of epilepsy treatment in the nine markets and will continue to have significant market share during the forecast period. Other key drugs include older generation AEDs such as Pfizer's Dilantin, Abbott's Depakote, and Novartis' Tegretol and Trileptal which still have significant usage due to their longevity in the market. However, the AED dominance landscape will continue to shift towards newer generation drugs particularly following the recent market entry of GlaxoSmithKline's Trobalt/Potiga and Eisai's Fycompa which both offer first-in-class mechanisms of action.
Lyrica is a compound with both analgesic and anticonvulsant properties that was developed by Pfizer as a more potent successor to gabapentin (Neurontin). Pregabalin is the active pharmaceutical ingredient in Lyrica, and it binds with high affinity to the alpha2-delta site (an auxiliary subunit of voltage-gated calcium channels) in CNS tissues. Blockade of these channels has been shown to inhibit the calcium-dependent release of a number of neurotransmitters. While pregabalin is a structural derivative of the inhibitory neurotransmitter GABA, it does not bind directly to GABA-A, GABA-B, or benzodiazepine receptors, and it does not augment GABA responses. Lyrica is available as both a capsule and solution for oral administration, and has been approved for the treatment of partial seizures, peripheral neuropathy (sensory neuropathy), fibromyalgia, postherpetic neuralgia (PHN), and diabetic neuropathy.
Scope
- Overview of Epilepsy, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Lyrica including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Lyrica for the top nine countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, China and India
Reasons to buy
See the original post here:
Research and Markets: Lyrica ( Epilepsy ) - Forecast and Market Analysis to 2022